Log In
BCIQ
Print this Print this
 

CKD-516

  Manage Alerts
Collapse Summary General Information
Company Chong Kun Dang Pharmaceutical Corp.
DescriptionTubulin inhibitor and vascular disrupting agent (VDA)
Molecular Target Tubulin
Mechanism of ActionMicrotubule depolymerization; Tubulin inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today